CD86 and cancer: Whether these signals are common across multiple cancer types is not known, but several of these receptor-ligand pairs (CXCR6-CXCL16, CTLA-4-CD86, LGALs9-CD44/PTPRC) have been shown to play roles in cancer modulation (60–62).